Combining metaphase cytogenetics with single nucleotide polymorphism arrays can improve the diagnostic yield and identify prognosis more precisely in myelodysplastic syndromes

References

• Greenberg PL, Stone RM, Al-Kali A, et al. NCCN guidelines insights: myelodysplastic syndromes, version 3.2022. J Natl Compr Canc Netw. 2022;20(2):106–117.
   PubMed Web of Science ®Google Scholar
• Gale RE. Evaluation of clonality in myeloid stem-cell disorders. Semin Hematol. 1999;36(4):361–372.
   PubMed Web of Science ®Google Scholar
• Arber DA, Orazi A, Hasserjian R, et al. The 2016 revision to the world health organization classification of myeloid neoplasms and acute leukemia. Blood. 2016;127(20):2391–2405.
   PubMed Web of Science ®Google Scholar
• Sole F, Luno E, Sanzo C, et al. Identification of novel cytogenetic markers with prognostic significance in a series of 968 patients with primary myelodysplastic syndromes. Haematologica. 2005;90:1168–1178.
   PubMed Web of Science ®Google Scholar
• Pozdnyakova O, Miron PM, Tang G, et al. Cytogenetic abnormalities in a series of 1,029 patients with primary myelodysplastic syndromes: a report from the US with a focus on some undefined single chromosomal abnormalities. Cancer. 2008;113(12):3331–3340.
   PubMed Web of Science ®Google Scholar
• Haase D, Germing U, Schanz J, et al. New insights into the prognostic impact of the karyotype in MDS and correlation with subtypes: evidence froma core dataset of 2124 patients. Blood. 2007;110(13):4385–4395.
   PubMed Web of Science ®Google Scholar
• Tiu RV, Gondek LP, O'Keefe CL, et al. Prognostic impact of SNP array karyotyping in myelodysplastic syndromes and related myeloid malignancies. Blood. 2011;117(17):4552–4560.
   PubMed Web of Science ®Google Scholar
• da Silva FB, Machado-Neto JA, Bertini V, et al. Single-nucleotide polymorphism array (SNP-A) improves the identification of chromosomal abnormalities by metaphase cytogenetics in myelodysplastic syndrome. J Clin Pathol. 2017;70(5):435–442.
   PubMed Web of Science ®Google Scholar
• Mullighan CG, Goorha S, Radtke I, et al. Genome-wide analysis of genetic alterations in acute lymphoblastic leukaemia. Nature. 2007;446(7137):758–764.
   PubMed Web of Science ®Google Scholar
• Maciejewski JP, Tiu RV, O'Keefe C. Application of array-based whole genome scanning technologies as a cytogenetic tool in haematological malignancies. Br J Haematol. 2009;146(5):479–488.
   PubMed Web of Science ®Google Scholar
• Gondek LP, Tiu R, O'Keefe CL, et al. Chromosomal lesions and uniparental disomy detected by SNP arrays in MDS, MDS/MPD, and MDS-derived AML. Blood. 2008;111(3):1534–1542.
   PubMed Web of Science ®Google Scholar
• Mohamedali A, Gäken J, Twine NA, et al. Prevalence and prognostic significance of allelic imbalance by single-nucleotide polymorphism analysis in low risk myelodysplastic syndromes. Blood. 2007;110(9):3365–3373.
   PubMed Web of Science ®Google Scholar
• MacKinnon RN. Analysis of chromothripsis by combined FISH and microarray analysis. Methods Mol Biol. 2018;1769:53–77.
   PubMedGoogle Scholar
• NCCN clinical practice guidelines in oncology (NCCN Guidelines®), myelodysplastic syndromes version 3; 2022. Available from: https://www.nccn.org.
   Google Scholar
• Greenberg PL, Tuechler H, Schanz J, et al. Revised international prognostic scoring system for myelodysplastic syndromes. Blood. 2012;120(12):2454–2465.
   PubMed Web of Science ®Google Scholar
• Shaffer LG, McGowan-Jordan J. An international system for human cytogenetic nomenclature. Basel: Karger; 2013.
   Google Scholar
• Makishima H, Rataul M, Gondek LP, et al. FISH and SNP-A karyotyping in myelodysplastic syndromes: improving cytogenetic detection of del(5q), monosomy 7, del(7q), trisomy 8 and del(20q). Leuk Res. 2010;34(4):447–453.
   PubMed Web of Science ®Google Scholar
• Gondek LP, Tiu R, Haddad AS, et al. Single nucleotide polymorphism arrays complement metaphase cytogenetics in detection of new chromosomal lesions in MDS. Leukemia. 2007;21(9):2058–2061.
   PubMed Web of Science ®Google Scholar
• Gondek LP, Haddad AS, O'Keefe CL, et al. Detection of cryptic chromosomal lesions including acquired segmental uniparental disomy in advanced and low-risk myelodysplastic syndromes. Exp Hematol. 2007;35(11):1728–1738.
   PubMed Web of Science ®Google Scholar
• Heinrichs S, Kulkarni RV, Bueso-Ramos CE, et al. Accurate detection of uniparental disomy and microdeletions by SNP array analysis in myelodysplastic syndromes with normal cytogenetics. Leukemia. 2009;23(9):1605–1613.
   PubMed Web of Science ®Google Scholar
• Hu Q, Chu Y, Song Q, et al. The prevalence of chromosomal aberrations associated with myelodysplastic syndromes in China. Ann Hematol. 2016;95(8):1241–1248.
   PubMed Web of Science ®Google Scholar
• Kralovics R, Passamonti F, Buser AS, et al. A gain-of-function mutation of JAK2 in myeloproliferative disorders. N Engl J Med. 2005;352(17):1779–1790.
   PubMed Web of Science ®Google Scholar
• Kralovics R, Guan YL, Prchal JT. Acquired uniparental disomy of chromosome 9p is a frequent stem cell defect in polycythemia vera. Exp Hematol. 2002;30(3):229–236.
   PubMed Web of Science ®Google Scholar
• Raghavan M, Lillington DM, Skoulakis S, et al. Genome-wide single nucleotide polymorphism analysis reveals frequent partial uniparental disomy due to somatic recombination in acute myeloid leukemias. Cancer Res. 2005;65(2):375–378.
   PubMed Web of Science ®Google Scholar
• Jankowska AM, Szpurka H, Tiu RV, et al. Loss of heterozygosity 4q24 and TET2 mutations associated with myelodysplastic/myeloproliferative neoplasms. Blood. 2009;113(25):6403–6410.
   PubMed Web of Science ®Google Scholar
• Dunbar AJ, Gondek LP, O'Keefe CL, et al. 250K single nucleotide polymorphism array karyotyping identifies acquired uniparental disomy and homozygous mutations, including novel missense substitutions of c-Cbl, in myeloid malignancies. Cancer Res. 2008;68(24):10349–10357.
   PubMed Web of Science ®Google Scholar
• Makishima H, Cazzolli H, Szpurka H, et al. Mutations of e3 ubiquitin ligase cbl family members constitute a novel common pathogenic lesion in myeloid malignancies. J Clin Oncol. 2009;27(36):6109–6116.
   PubMed Web of Science ®Google Scholar
• Jasek M, Gondek LP, Bejanyan N, et al. TP53 mutations in myeloid malignancies are either homozygous or hemizygous due to copy number-neutral loss of heterozygosity or deletion of 17p. Leukemia. 2010;24(1):216–219.
   PubMed Web of Science ®Google Scholar
• Stephens PJ, Greenman CD, Fu B, et al. Massive genomic rearrangement acquired in a single catastrophic event during cancer development. Cell. 2011;144(1):27–40.
   PubMed Web of Science ®Google Scholar
• Ostapińska K, Styka B, Lejman M. Insight into the molecular basis underlying chromothripsis. IJMS. 2022;23(6):3318.
   Google Scholar
• Gao J, Chen YH, Mina A, et al. Unique morphologic and genetic characteristics of acute myeloid leukemia with chromothripsis: a clinicopathologic study from a single institution. Hum Pathol. 2020;98:22–31.
   PubMed Web of Science ®Google Scholar
• Abáigar M, Robledo C, Benito R, et al. Chromothripsis is a recurrent genomic abnormality in high-risk myelodysplastic syndromes. PLoS One. 2016;11(10):e0164370.
   PubMed Web of Science ®Google Scholar
• Yeung CCS, McElhone S, Chen XY, et al. Impact of copy neutral loss of heterozygosity and total genome aberrations on survival in myelodysplastic syndrome. Mod Pathol. 2018;31(4):569–580.
   PubMed Web of Science ®Google Scholar
• Evans AG, Ahmad A, Burack WR, et al. Combined comparative genomic hybridization and single-nucleotide polymorphism array detects cryptic chromosomal lesions in both myelodysplastic syndromes and cytopenias of undetermined significance. Mod Pathol. 2016;29(10):1183–1199.
   PubMed Web of Science ®Google Scholar
• Della Porta MG, Tuechler H, Malcovati L, et al. Validation of WHO classification-based prognostic scoring system (WPSS) for myelodysplastic syndromes and comparison with the revised international prognostic scoring system (IPSS-R). a study of the international working group for prognosis in myelodysplasia (IWG-PM. Leukemia. 2015;29(7):1502–1513.
   PubMed Web of Science ®Google Scholar
• Bersanelli M, Travaglino E, Meggendorfer M, et al. Classification and personalized prognostic assessment on the basis of clinical and genomic features in myelodysplastic syndromes. J Clin Oncol. 2021;39(11):1223–1233.
   PubMed Web of Science ®Google Scholar
• Nazha A, Komrokji R, Meggendorfer M, et al. Personalized prediction model to risk stratify patients with myelodysplastic syndromes. J Clin Oncol. 2021;39(33):3737–3746.
   PubMed Web of Science ®Google Scholar
• Bernard E, Tuechler H, Greenberg PL, et al. Molecular international prognostic scoring system for myelodysplastic syndromes. NEJM Evidence. 2022;1(7). DOI:https://doi.org/10.1056/EVIDoa2200008
   Google Scholar
• Khoury JD, Solary E, Abla O, et al. The 5th edition of the world health organization classification of haematolymphoid tumours: Myeloid and histiocytic/dendritic neoplasms. Leukemia. 2022;36(7):1703–1719.
   PubMed Web of Science ®Google Scholar